Funding, News and Announcements

» Go to news main

Myeloma Canada and Pfizer Canada (RFP)

Posted by Jaq-Lin Larder on March 20, 2023 in Research Funding

Myeloma Canada and Pfizer Canada are pleased to collaborate to offer a grant opportunity to support Quality Improvement (QI) projects that will advance the quality of care and best practices around treatment for patients with relapsed/refractory multiple myeloma (RRMM) receiving bispecific antibody (BsAb) treatment.

This RFP is being issued by both organizations. Myeloma Canada is the lead organization for review and evaluation of proposals. A review committee, led by Myeloma Canada, will make decisions on which proposals will receive funding.

Read more about this call here.


Internal: May 18, 2023 at 4:30pm. Contact email is For additional resources, click here for guidance on internal deadlines and submission processes.

Funder: June 1, 2023. Contacts are Gabriele Colasurdo, or Amanda Kaczerski,